Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
JAK3 mutation
i
Other names:
JAK3, Janus Kinase 3, Tyrosine-Protein Kinase JAK3, Leukocyte Janus Kinase, JAK-3, L-JAK, Janus Kinase 3 (A Protein Tyrosine Kinase Leukocyte), JAK3_HUMAN, JAKL, LJAK
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3718
Related biomarkers:
Mutation
CNA
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older (NCT02494882)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/29/2024
Initiation :
06/29/2015
Primary completion :
06/01/2025
Completion :
06/01/2025
ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP
|
BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R
|
dasatinib • Jakafi (ruxolitinib) • dexamethasone
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774)
Phase N/A
Massive Bio, Inc.
Massive Bio, Inc.
Recruiting
Phase N/A
Massive Bio, Inc.
Recruiting
Last update posted :
03/15/2024
Initiation :
01/01/2018
Primary completion :
12/01/2026
Completion :
06/01/2027
EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703
|
HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation
Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma (NCT05273099)
Phase N/A
Università degli Studi di Ferrara
Università degli Studi di Ferrara
Recruiting
Phase N/A
Università degli Studi di Ferrara
Recruiting
Last update posted :
04/12/2022
Initiation :
03/01/2022
Primary completion :
03/01/2023
Completion :
12/01/2023
EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A
|
JAK3 mutation
Share
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.